Reilly Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Reilly Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,250	Closed	-$8K	–	1086
2021 Q1	$8K	Hold	1,250	–	–	﹤0.01%	741
2020 Q4	$7K	Hold	1,250	–	–	﹤0.01%	680
2020 Q3	$7K	Hold	1,250	–	–	﹤0.01%	632
2020 Q2	$9K	Hold	1,250	–	–	﹤0.01%	615
2020 Q1	$6K	Hold	1,250	–	–	﹤0.01%	661
2019 Q4	$10K	Hold	1,250	–	–	﹤0.01%	636
2019 Q3	$9K	Hold	1,250	–	–	﹤0.01%	658
2019 Q2	$10K	Hold	1,250	–	–	﹤0.01%	678
2019 Q1	$12K	Hold	1,250	–	–	﹤0.01%	643
2018 Q4	$10K	Hold	1,250	–	–	﹤0.01%	655
2018 Q3	$22K	Hold	1,250	–	–	﹤0.01%	534
2018 Q2	$12K	Hold	1,250	–	–	﹤0.01%	624
2018 Q1	$5K	Hold	1,250	–	–	﹤0.01%	786
2017 Q4	$5K	Hold	1,250	–	–	﹤0.01%	787
2017 Q3	$2K	Hold	1,250	–	–	﹤0.01%	912
2017 Q2	$1K	Hold	1,250	–	–	﹤0.01%	920
2017 Q1	$2K	Hold	1,250	–	–	﹤0.01%	855
2016 Q4	$1K	Buy	+1,250	New	+$1.41K	﹤0.01%	810

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Reilly Financial Advisors's VKTX Position: Q2 2021 in Review

Reilly Financial Advisors sold out of Viking Therapeutics (VKTX) in Q2 2021, closing a stake of 1,250 shares — an estimated $8K sold.

Reilly Financial Advisors first reported a position in VKTX in Q4 2016 and held it in 18 quarters. The position peaked at $22K in Q3 2018. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2021.

Reilly Financial Advisors reported no remaining Viking Therapeutics position as of Q2 2021 after selling out during the quarter.
Reilly Financial Advisors sold 1,250 Viking Therapeutics shares in Q2 2021, an estimated $8K.
Reilly Financial Advisors first reported a position in Viking Therapeutics in Q4 2016 and held it in 18 quarters.
Reilly Financial Advisors's Viking Therapeutics position peaked at $22K in Q3 2018.
138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2021.

Based on Reilly Financial Advisors's 13F filing for Q2 2021, filed 3 Aug 2021.